<DOC>
	<DOCNO>NCT01723826</DOCNO>
	<brief_summary>This Phase II , open-label extension ( OLE ) , multicenter study evaluate long-term safety tolerability crenezumab participant mild moderate Alzheimer 's disease participate complete treatment period Phase II Study ABE4869g ( NCT01343966 ) ABE4955g ( NCT01397578 ) . Participants receive placebo Study ABE4869g ( NCT01343966 ) ABE4955g ( NCT01397578 ) receive crenezumab . Anticipated time study treatment 144 week .</brief_summary>
	<brief_title>A Long-Term Safety Extension Studies ABE4869g ABE4955g Participants With Mild Moderate Alzheimer 's Disease Treated With Crenezumab</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Previous participation Study ABE4869g ABE4955g completion Week 73 visit Adequate visual auditory acuity , investigator 's judgment , allow neuropsychological test Availability person ( `` caregiver '' ) provide information activity daily live behavior order complete studyspecific assessment Diagnosis probable Alzheimer 's disease accord National Institute Neurological Communication Disease Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion ( McKhann et al . 1984 ) MiniMental State Examination ( MMSE ) score 10 screening ( Folstein et al . 1975 ) For male participant partner reproductive potential , agreement use reliable mean contraception ( e.g. , condom ) study least 8 week follow last dose study drug For female participant , negative pregnancy test screen Early treatment and/or study discontinuation prior completion Week 73 visit Genentech Study ABE4869g ABE4955g Early discontinuation treatment schedule prior version Study GN28525 safety reason . If treatment discontinuation occur safety reason , participant may restart dose extended treatment schedule offer amendment Study GN28525 Inability tolerate Magnetic Resonance Imaging ( MRI ) procedures contraindication MRI Female participant reproductive potential : Female participant must either undergone document surgical sterilization experience menstruation least 12 consecutive month Severe unstable medical condition , opinion investigator Sponsor , would interfere participant 's ability complete study assessment would require equivalent institutional hospital care History presence clinically evident vascular disease potentially affect brain History severe , clinically significant central nervous system trauma History presence clinically relevant intracranial tumor Presence infection affect brain function history infection result neurologic sequelae History presence systemic autoimmune disorder potentially cause progressive neurologic disease History presence neurologic disease Alzheimer 's disease may affect cognition History severe allergic , anaphylactic , hypersensitivity reaction chimeric , human , humanized antibody fusion protein Evidence malignancy ( except squamous cell cancer basal cell cancer skin ) , acute infection , renal failure require dialysis , unstable medical disease relate Alzheimer 's disease , investigator 's opinion , would preclude participant 's participation . Cancer actively treat anticancer therapy radiotherapy well cancer consider low probability recurrence allow History presence atrial fibrillation , investigator 's judgment , pose risk future stroke Chronic kidney disease Stage great equal ( &gt; = ) 4 , accord National Kidney Foundation Kidney Disease Outcomes Quality Initiative ( NKF KDOQI ) guideline chronic kidney disease ( CKD ) Impaired hepatic function Impaired coagulation ( activate partial thromboplastin time [ aPTT ] great [ &gt; ] 1.2 time upper limit normal [ ULN ] ) Platelet count le ( &lt; ) 100,000 per microliter ( mcL ) Presence screen superficial siderosis central nervous system , 8 cerebral microhemorrhages , evidence prior cerebral macrohemorrhage Presence screening significant cerebral abnormality , include ARIAE Treatment anticoagulation medication within 2 week prior enrollment . Clopidogrel , dipyridamole , aspirin permit Treatment anticholinergic antidepressant , typical antipsychotic , barbiturate within 2 week prior enrollment . All antidepressant atypical antipsychotic allow certain restriction define protocol Chronic use opiate , opioids , benzodiazepine Any biologic therapy within 75 week prior enrollment Any investigational agent ( crenezumab ) within 75 week prior enrollment Treatment anticholinergic antidepressant , typical antipsychotic , barbiturate , narcotic within 5 halflives 3 month prior screen , whichever long . All antidepressant atypical antipsychotic allow . Chronic use benzodiazepine allow ; however , intermittent use benzodiazepine allow , except within 2 day prior neurocognitive assessment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>